

Review

Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine

Noriko Kimura ¹, Kazuhiro Takekoshi ², Mitsuhide Naruse ³

¹ Department of Clinical Research Pathology Division, Department of Diagnostic Pathology, National Hospital Organization Hakodate Hospital, Hakodate, Hokkaido, Japan; kimura-path@hnh.hosp.go.jp

² Division of Sports Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; k-takemd@md.tsukuba.ac.jp

³ Department of Endocrinology, Metabolism, and Hypertension, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan; mnaruse@kyotolan.hosp.go.jp

* Correspondence: kimura-path@hnh.hosp.go.jp; Tel.: 81+138516281(ext. 324)

Abstract: Pheochromocytoma and sympathetic paraganglioma (PPGL) are rare neuroendocrine tumors characterized by catecholamine production in the adrenal medulla and extra-adrenal paraganglia. PPGL with metastasis was termed malignant PPGL. However, the distinction between “benign” and “malignant” PPGLs has been debated. Currently, all PPGLs are believed to have some metastatic potential and are assigned malignant tumors (ICD-O /3) by the WHO Classification of Endocrine Organs (2017, 4th edition). Therefore, the previous categories benign and malignant PPGL have been eliminated in favor of a risk stratification approach. The Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) is a tool for risk stratification for predicting metastasis and the prognosis of patients. At least 30% of PPGLs are hereditary, with 20 genes identified and genotype-phenotype correlations clarified. Of these, VHL, RET, and NF1 have been well investigated and are the primary cause of bilateral PCC. In addition, succinate dehydrogenase gene subunits SDHB and SDHD are strongly correlated with extra-adrenal location, younger age, multiple tumors, metastasis, and poor prognosis. Disease stratification by catecholamine phenotype and molecular profiling correlates with histological grading by GAPP. PPGLs should be understood comprehensively based on clinical, biochemical, molecular, and pathological data for patient care. A flow chart for pathological diagnosis is included.

Keywords: pheochromocytoma¹; paraganglioma²; GAPP³; metastasis⁴; prognosis⁵; catecholamine⁶; gene mutation⁷; Immunohistochemistry⁸; Pathology; Diagnosis

1. Introduction

Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors that arise in the adrenal medulla and the extra-adrenal paraganglia, respectively. There are two types of PGL, parasympathetic and sympathetic. Both PCC and sympathetic PGL are catecholamine-producing tumors, which often have a common genetic basis and functional similarities. The incidence of PCC and PGL (PPGLs) is 1–3 individuals per 100,000, with 500–1600 new cases in the United States per year [1, 2]. The incidence of PGL is 10–15% that of PCC. PPGLs are characterized by their broad age of incidence, familial association, multifocal tendency, and metastasis. At least 30% of PPGLs are hereditary, and susceptible genes have been identified [1, 2]. A prolonged hypoxic state such as Eisenmenger’s syndrome may be related to PPGL pathogenesis [3]. The risk of metastasis is 10–20% in PCC, and up to 50% in PGL depending on the genotype [4–6]. The data presented here are primarily regarding PCC and sympathetic PGLs.

Since the beginning age of PPGL research about 50 years ago [7], PPGLs have been classified into either benign or malignant tumors. Despite of much research, there are no universally acceptable histologic criteria predicting metastasis. Thus, histology has been considered useless for differentiating between benign and malignant tumors; malignant PCC was defined only by the presence of metastasis (World Health Organization [WHO] 2004) [8]. The lack of a histological, molecular, or genetic criteria that can absolutely differentiate between benign and malignant PCC/PGL presents an enormous clinical challenge [9]. As a result, the European Clinical Guideline decided that all patients with PPGLs should be followed up for at least 10 years, and high-risk patients (young, genetic disease, large tumor, and PGL) should be offered lifetime annual follow ups [10].

Japan was found to have a similar situation. A nationwide survey of PPGLs determined in 2010 that 2920 patients had PPGLs, 320 of which had metastases [11]. Among patients with 320 malignant PPGL, 37% were initially diagnosed as benign and 60% showed absence of metastasis at initial operation. It was concluded from these results that the diagnosis of benign is not correct for PPGLs with no metastasis at the time of the initial operation, and long-term follow up is necessary for patients with PPGL even though the pathologic diagnosis is benign. Based on such clinical data, the WHO Endocrine Tumour Classification 4th edition (2017) decided on a New Concept that all PPGLs have some metastatic potential, and assigned an International Classification of Diseases for Oncology (ICD-O)-3 (malignant tumors) for all PPGLs, eliminating the previous categories of benign and malignant tumors in favor of an approach based on risk stratification [1-2]. Risk stratification is required to tailor the follow-up protocol after complete resection of PPGLs [12].

2. Pathologic risk stratification

To break through the difficulty of pathologic diagnosis of PCC, Thompson used a scoring system, Pheochromocytoma of the Adrenal Gland Scaled Score (PASS), which consists of 12 parameters and scores up to 20 points. Tumors with a PASS score ≥ 4 were defined as having increased metastatic potential, whereas those with a score < 4 were considered not to have metastatic potential [13]. The utility of PASS was validated by seven experienced pathologists that concluded there is significant interobserver and intraobserver variation, and they could not currently recommended PASS for clinical prognostication [14]. Kimura et al. [15] then developed another scoring system, Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP), composed of six parameters that have been considered prognostic factors in many previous reports, including some from PASS and Kimura's own experience.

2.1. GAPP

GAPP is characterized by first evaluating the malignant grade of PCC and sympathetic PGL together, in contrast to PASS, which is only for evaluating PCC. Next, catecholamine phenotypes are analyzed, and finally, the malignancy is graded as low risk, intermediate risk, or high risk for metastasis. Thus, predicting patient survival is based on risk grade instead of benign or malignant PPGLs. Histological grading is based on a scoring system composed of six parameters (risk factors for metastasis): histological pattern, cellularity, comedo necrosis, capsular/vascular invasion, Ki67 labeling index, and catecholamine phenotype, with a total of 10 possible points (Table 1). A score of 0–2 is well-, 3–6 is moderately, and 7–10 is poorly differentiated types (Table 2). Of these PPGLs, approximately 70% are well-differentiated, which very rarely metastasize, and no patients died of this type of tumor. The well-differentiated tumors are compatible with so-called benign PPGLs. In the remaining PPGLs, approximately 20% are moderately and 10% are poorly differentiated, with high metastatic potential (60% and 88%, respectively). The five-year survival rates of the patients are 100%, 67%, and 22% for well-, moderately, and poorly differentiated PPGLs, respectively.

Effectively, a GAPP score of 0–2 is low risk, of 3–6 is intermediate risk, and of 7–10 is high risk (Table 3). A clinical requirement for risk stratification is urgent as the clinical course of patients with malignant PPGL is remarkably variable, and an individualized approach to patients with metastatic PPGL is warranted [16]. Furthermore, risk stratification is required to tailor the follow-up protocol after complete resection of PPGL [17]. GAPP could be utilized for urgent clinical requirements, as Koh et al. has validated GAPP for the prediction of metastatic potentiality [18].

2.2. Catecholamine type and metastasis

PPGLs are characterized by production of catecholamine. Catecholamines such as adrenaline, noradrenaline, and dopamine, as well as tumor location and ratio of metastasis are intimately correlated in PPGLs. Adrenaline-producing tumors, those that produce adrenaline only or adrenaline plus noradrenaline, are 100% of adrenal gland origin, with a metastatic ratio of 13%. Noradrenaline-producing PPGLs are those tumors in which noradrenaline only or noradrenaline plus dopamine are produced; 50% of PCCs and 100% of PGLs are of this type. The metastatic ratio is 2 times higher in noradrenaline-type than adrenaline-type tumors in PCCs, and approximately 3 times higher in noradrenaline-type tumors in combined PCCs and PGLs (Table 4). Thus, catecholamine type constitutes an important risk factor. Noradrenaline-producing PPGLs lack phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts noradrenaline to adrenaline, and are considered to be less differentiated than adrenaline-producing tumors based on catecholamine synthesis. In addition, dopamine hypersecretion is considered a feature of immaturity and a marker for malignant PPGLs [19]. Dopamine-producing PPGLs are typically non-functioning; Eisenhofer et al. [20] reported that the plasma level of methoxytyramine, the O-methylated metabolite of dopamine, is 4.7-fold higher in patients with metastases than in those without, suggesting its use as a potential biomarker. The mechanisms underlying non-functioning PPGLs are not fully understood. A deficiency of catecholamine synthesizing enzymes may partially, but not fully, account for this phenomenon [21]. Therefore, the correlation of non-functioning PPGLs and patient prognosis should be further investigated.

3. Molecular risk stratification

There are 20 susceptibility genes for PPGLs at present: *SDHA*, *SDHAF2*, *SDHC*, *KIF1B*, *TMEM127*, *FH*, *NF1*, *RET*, *VHL*, *SDHD*, *SDHB*, *MAX*, *HRAS*, *ATRX*, *EPAS1/HIF2A*, *MEN1*, *EGLN1/PDH2*, *EGLN2/PDH1*, *MDH2*, and *IDH1* in various types of mutations including germline only, germline and somatic, somatic only, somatic and somatic mosaicism, and single patients or families [22–23]. Germline mutations in predisposition genes are found in 25–30% of PPGLs overall [24]. Germline mutations in succinate dehydrogenase subunit x (*SDHx*) including *SDHA*, *SDHB*, *SDHC*, *SDHD*, and *SDHAF2* are the most common genetic cause of PPGLs, occurring in up to 25% of cases [25–26]. The next most commonly associated genes are *VHL* (4–10%), *RET* (1–5%), and *NF1* (1–5%) [27]. PGL1 syndrome (*SDHD*) and PGL2 syndrome (*SDHAF2*) are notable for their high frequency of multifocal tumor development and for parent-of-origin inheritance. PGL4 syndrome (*SDHB*) is notable for an increased risk of malignant PPGLs. PGL3 syndrome (*SDHC*) and PGL5 syndrome (*SDHA*) are less common [27]. Human hereditary paraganglioma pheochromocytoma syndrome (HPPS), including *SDH* types 1–5, is an autosomal dominant disorder characterized by familial predisposition to PPGLs and occasionally combined with renal cell carcinomas, gastrointestinal stromal tumors, neuroendocrine tumors of the pancreas and intestine, and rarely, pituitary adenomas [28].

3.1. Immunohistochemistry for gene mutations

Loss of SDHB protein immunoreactivity in tumors with *SDHx* mutation is reported with 100% sensitivity and 84% specificity [29]. The following studies validated that SDHB immunohistochemistry can be used for screening of patients with HPPS using paraffin-embedded tumor tissues [30, 31, 32]. The *SDHB* mutation is the only established factor that indicates future metastasis. Therefore, it is important to perform SDHB immunohistochemistry for all PPGLs except the adrenaline-producing type. In addition to *SDHx* PPGLs, *VHL* tumors are sometimes SDHB-negative or stain very weakly. Tumors associated with *SDH* deficiency display notable upregulation of hypoxia-responsive genes, and this is shared by PPGLs associated with mutations in *VHL* [33, 34]. Patients with SDHB-negative tumors should be carefully monitored for a long period of time due to the high possibility of metastasis. In addition, immunohistochemistry for SDHA-negative or MAX-negative tumors indicate an *SDHA*- [35] or *MAX*-mutation [36]. Therefore, if immunohistochemical analysis is negative for SDHB, SDHA, or MAX, gene analysis should be performed to determine if a mutation is actually present, particularly in younger patients or patients with bilateral, extra-adrenal, or familial PPGLs.

3.2. Differential diagnosis and risk stratification

A microarray-gene expression profile demonstrates that Cluster 1 and Cluster 2 clearly differentiate between and correlate with types of genes, signaling pathways, and tumor phenotypes [37, 38, 39, 40]. Furthermore, Cluster and GAPP produce very similar results regarding genotype and phenotype correlation (Table 5). The combined data of Cluster and GAPP may greatly contribute to identifying and selecting the type of therapy and treatment patients receive.

4. Flow chart for differential diagnosis

Pathological diagnosis of PPGLs by general pathologists is sometimes difficult due to their very low incidence and histological variety, particularly in cases of non-functioning tumors. For example, adrenocortical carcinoma and neuroendocrine tumors are sometimes misdiagnosed as PPGLs. Gastrointestinal stromal tumors, adult neuroblastoma, and alveolar soft part sarcoma are rarely needed for differential diagnosis. Immunohistochemistry is the most useful tool for differential diagnosis. All functioning and non-functioning PPGLs express chromogranin A (CgA) and dopamine β -hydroxylase (DBH) [21]. CgA is an essential protein for PPGLs as well as for normal adrenal medulla. Thus, if immunohistochemistry for CgA is negative, PPGLs should be ruled out. Other neuroendocrine markers such as synaptophysin and CD56 (neural cell adhesion molecule) are general markers for neuroendocrine tumors including PPGLs, as well as some adrenocortical tumors. Adrenocortical carcinomas or neuroendocrine tumors of other organs are sometimes misdiagnosed as non-functioning PPGLs. Thus, if only synaptophysin and CD56 are positive, this is not sufficient evidence for a diagnosis of PPGL. Tyrosine hydroxylase (TH) and DBH are essential enzymes for catecholamine synthesis, and both antibodies are useful for identification of catecholamine-producing tumors. However, some non-functioning PPGLs lack TH immunoreactivity, making DBH a better marker than TH for identification of PPGLs [21, 36] (Figure 1). A flow chart for pathologically differential diagnosis of PPGLs is included in Table 6.

5. Summary and conclusions

Recent research on PPGLs shows remarkable progress, and comprehensive study of molecular, biochemical, and pathological investigations revealed the complicated problems associated with PPGLs. However, many issues remain that require further research, in

particular, clarifying the mechanism of metastasis and developing a therapy for highly malignant PPGLs.

Figure 1. Nonfunctioning retroperitoneal paraganglioma




Figure 1A Non-functioning retroperitoneal paraganglioma, GAPP score is 9 points (large irregular zellballen pattern, high cellularity, comedo necrosis, vascular invasion, 14% of Ki67 labelling index).

Figure 1B Chromogranin A immunostaining shows dot-like reactivity at Golgi area of tumor cells.

Figure 1C Tyrosine hydroxylase immunohistochemistry shows negative staining in all tumor cells. Inset: Internal control of sympathetic ganglion cells adjacent to the tumor.

Figure 1D Dopamine beta-hydroxylase immunostaining shows positive reaction in tumor cells of this non-functioning paraganglioma.

Table 1 GAPP : parameters and score

Parameters	Scoring point
Histological Pattern	
zellballen	0
large and irregular cell nest	1
pseudorosette (even focal)	1
Cellularity	
low (less than 150 cells/U*)	0
moderate (150-250 cells/U*)	1
high (more than 250 cells/U*)	2
Comedo Necrosis	
absence	0
presence	2
Vascular or Capsular Invasion	
absence	0
presence	1
Ki67 Labelling Index	
less than 1%	0
1-3%	1
more than 3%	2
Catecholamine Type	
Adrenaline type (A**, or A+NA***)	0
Noradrenaline type (NA, or NA+DA****)	1
Non-functioning type	0
Total maximum score	10
U*: Cells in Unit of 10 x 10 mm micrometer under high power field (x400)	
A**: Adrenaline, NE****: Noradrenaline, DA****: Dopamine	

Table 2 GAPP: Score and Grading

Score	Grading
0-2:	well differentiated type
3-6:	moderately differentiated type
7-10:	poorly differentiated type

Table 3 GAPP Score and Risk Stratification

Total Score (points)	Histological grade (frequency)	Metastatic rate	5-year survival (%)	Risk Stratification
0-2	Well differentiated (68%)	3.6%	100	low
3-6	Moderately differentiated (22%)	60.0%	66.8	intermediate
7-10	Poorly differentiated (10%)	88.2%	22.4	high

Table 4 Catecholamine types, tumor locations and metastasis

Catecholamine types	Number of patients	Number of metastasis	Ratio of metastasis (%)
Epinephrine	78	11	13.0
Norepinephrine	79	29	36.7
(Adrenal)	(49)	(13)	(26.5)
(Extra-adrenal)	(30)	(15)	(50.0)
Non-functioning (Extra-adrenal)	6	1	16.7
Total Number	163	40	24.5

Table 5 Correlation of Cluster Stratification and GAPP

	Cluster 1	Cluster 1	Cluster 2
Gene	SDH x (SDHA, B, C, D), SDHAF2, HIF2, KIF1B, PHD2, HRAS, FH, HIF-1	VHL Sporadic noradrenergic	RET, NF1, MAX, TMEM127, Sporadic adrenergic
Signaling pathways	Pseudo hypoxia (HIF-1a) & aberrant VEGF signaling		Kinase signalling : PI3 kinase/AKT, RAS/RAF/ERK, & mTORC1/p70S6K
Catecholamine type	DA, mixed DA & NA	Noradrenaline	Adrenaline
Secretory phenotype	Immature	Immature	Mature
Tumor location	Extra-adrenal	Adrenal & Extra-adrenal	Adrenal
Age of presentation	Early (under 30 year-old)	Early	Late
Metastasis	Frequent	Occasional	Rare
Metastatic risk by GAPP ¹⁵⁾¹⁹⁾	Intermediate ~ High	Low ~ Intermediate	Low

Cluster Stratification : Microarray-gene expression profiling²⁰⁾
DA: Dopamine; NA:Noradrenaline; A: Adrenaline

Table 6 Flow chart for differential diagnosis of PPGLs

Tumor location	CA-producing	Immunohistochemistry	Pathologic diagnosis
Adrenal	Yes, (Adrenaline +)	CgA+, DBH+, SDHB +	PCC => GAPP
	Yes, (Noradrenaline +)	CgA+, DBH+, SDHB + or -	PCC => GAPP
	Nonfunctioning or unknown	CgA+, DBH+, SDHB + or -	PCC => GAPP
	No, or unknown	CgA -, SP+/CD56 +	adrenocortical tumor
Extra-adrenal	Yes,	CgA+, DBH+, SDHB + or -	PGL => GAPP
	No, or unknown	CgA-, SP+/CD56 +	NETs, (adult) NB
		CgA -, SP-/CD56 -	RCC, GIST, ASPS, etc.

CA: catecholamine, CgA: chromogranin A, DBH: dopamine β-hydroxylase, SDHB: succinate dehydrogenase subunit B, PCC: pheochromocytoma, PGL: paraganglioma, GAPP: grading of adrenal pheochromocytoma and paraganglioma, SP: synaptophysin, CD56: neural cell adhesion molecule, NETs: neuroendocrine tumors, NB: neuroblastoma, RCC: renal cell carcinoma, GIST: gastrointestinal stromal tumor, ASPS: alveolar soft part sarcoma

Author Contributions: N.K. conducted the research and wrote the paper; K.T. and M.N. reviewed the paper.

Funding: This research was funded by Japan Agency for Medical Research and Development (AMED) under Grant Number JP18ek0109352 (NK).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Tischler A.S., de Krijger RR et al. Pheochromocytoma. In: WHO Classification of Tumors of Endocrine Organs. 4th ed.; Lloyd RV, Osamura RY, Kloppel G, et al., Eds.; IARC Press: Lyons, France, 2017; pp183-189, ISBN 978-92-832-4493-6

- 204 2. Kimura N, Capella C et al. Extraadrenal paraganglioma. In: WHO Classification of Tumors of
205 Endocrine Organs. 4th ed.; Lloyd RV, Osamura RY, Kloppel G, et al., Eds.; IARC Press: Lyons,
206 France, **2017**; pp p190-195, ISBN 978-92-832-4493-6
- 207 3. Bellingham GA, Dhir AK, Luke PP. Case report: retroperitoneal endoscopic pheochromocytoma
208 removal in an adult with Eisenmenger's syndrome. *Can J Anaesth.* **2008**, 55, 295–301.
- 209 4. Goffredo P, Sosa JA, Roman SA (2013). Malignant pheochromocytoma and paraganglioma: a
210 population level analysis of long-term survival over two decades. *J Surg Oncol.* **2013**, 107, 659–64.
- 211 5. Harari A, Inabnet WB 3rd. Malignant pheochromocytoma: a review. Malignant
212 pheochromocytoma: a review. *Am J Surg.* **2011**, 201, 700–8.
- 213 6. Korevaar TI, Grossman AB. Pheochromocytomas and paragangliomas: assessment of malignant
214 potential. *Endocrine.* **2011**, 40, 354–65.
- 215 7. Neville AM: The adrenal medulla. In *Functional pathology of the human adrenal gland.*
216 Symington T, Eds.; E&S Livingstone LTD, Edinburgh, England, **1969**; pp 219-324.
- 217 8. Thompson LD, Young JR. WF et al.: Malignant adrenal phaeochromocytoma. In: World Health
218 Organization Classification of Tumours Pathology & Genetics Tumours of Endocrine Organs. 3rd
219 ed; DeLellis RA, Lloyd RV, et al. Eds.; IARC, Lyon, France, **2004**; pp147-150. ISBN 92 832 24167
- 220 9. Roman-Gonzalez A, Jimenez C: Malignant pheochromocytoma-paraganglioma: pathogenesis,
221 TNM staging, and current clinical trials. *Curr Opin Endocrinol Diabetes Obes.* 2017, 24, 174-183.
- 222 10. Plouin PF, et al. European Society of Endocrinology Clinical Practice Guideline for long-term
223 follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. *Eur J Endocrinol.*
224 **2016**; 174, G1-G10.
- 225 11. Naruse M, PHEO-J Study Group 2011 Nationwide survey and PHEO network for the study of
226 pheochromocytoma/paraganglioma in Japan (PHEO-J). *Endocrine Reviews*, **2011**, 32, Meeting
227 Abstracts: P2–631.
- 228 12. Amar L, Lussey-Lepoutre C, Lenders JW, Djadi-Prat J, Plouin PF, Steichen O. NAGEMENT OF
229 ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of
230 pheochromocytomas and paragangliomas: a systematic review and meta-analysis. *Eur J Endocrinol.*
231 **2016**; 175, R135-45.
- 232 13. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign
233 from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. *Am J*
234 *Surg Pathol.* **2002**, 26, 551-566.
- 235 14. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F, et al. Observer
236 variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. *Am J*
237 *Surg Pathol.* **2009**, 33, 599-608.
- 238 15. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Pathological
239 grading for predicting metastasis in phaeochromocytoma and paraganglioma. *Endocr Relat Cancer.*
240 **2014**, 21, 405-414.
- 241 16. Hamidi OI, Young WF Jr et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients
242 Over 55 Years. *J Clin Endocrinol Metab.* **2017**, 102, 3296-3305.

- 243 17. Amar L, et al. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after
244 complete resection of pheochromocytomas and paragangliomas: a systematic review and
245 meta-analysis. *Eur J Endocrinol.* **2016**, 175, R135-45.
- 246 18. Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, Hong SJ, Song DE & Lee SH 2017
247 Validation of pathological grading systems for predicting metastatic potential in
248 pheochromocytoma and paraganglioma. *PLoS ONE*, **2017**, 12 e0187398.
- 249 19. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den
250 Meiracker AH, Stijnen TH, Boomsma F. The value of plasmamarkers for the clinical behaviour of
251 phaeochromocytomas. *Eur J Endocrinol*, **2002**, 147, 85–94.
- 252 20. Eisenhofer G, Tischler A, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma
253 and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. *Endocr*
254 *Pathol.* **2012**, 23, 4-14.
- 255 21. Kimura N, Miura Y, Nagatsu I, Nagura H. Catecholamine synthesizing enzymes in 70 cases of
256 functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. *Virchows*
257 *Arch A Pathol Anat Histopathol.* **1992**, 421, 25-32.
- 258 22. King KS, Pacak K. Familial pheochromocytomas and paragangliomas. *Mol. Cell Endocrinol.*
259 **2014**, 386, 92–100.
- 260 23. Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic
261 heterogeneity. *Nat. Rev. Cancer.* **2014**, 14, 108–119.
- 262 24. Gimenez-Roqueplo AP, Dahia PL & Robledo M. Update in the genetics of paraganglioma and
263 pheochromocytoma and hereditary syndromes. *Hormone and Metabolic Research.* **2012**, 44,
264 328–333.
- 265 25. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdic CM, Savul SA, McLeod DR, Yee HA,
266 Brackmann DE, Slattery WH III, Myers EN et al. Prevalence of SDHB, SDHC, and SDHD germline
267 mutations in clinic patients with head and neck paragangliomas. *J Medical Genetics* **2002**, 39
268 178–183.
- 269 26. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic
270 pheochromocytoma. *N Engl J Med.* **2002**, 346, 1459–66.
- 271 27. Benn, D.E., Robinson, B.G., Clifton-Bligh, R.J., 15 YEARS OF PARAGANGLIOMA: Clinical
272 manifestations of paraganglioma syndromes types 1-5. *Endocr Relat Cancer.* **2015**, 22, T91–103.
- 273 28. Tischler AS et al. Familial paraganglioma-phaeochromocytoma syndromes caused by SDHB,
274 SDHC, and SDHD mutations. In: WHO Classification of Tumors of Endocrine Organs. 4th ed.;
275 Lloyd RV, Osamura RY, Kloppel G, et al., Eds.; IARC Press: Lyons, France, **2017**; pp 262-265, ISBN
276 978-92-832-4493-6
- 277 29. van Nederveen FH, et al.: An immunohistochemical procedure to detect patients with
278 paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a
279 retrospective and prospective analysis. *Lancet Oncol.* **2009**, 10, 764-771.
- 280 30. Papatomas TG, et al. SDHB/SDHA immunohistochemistry in pheochromocytomas and
281 paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a
282 Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). *Mod*
283 *Pathol.* **2015**, 28, 807–821.

- 284 31. Gill AJ, Benn DE, Chou A, Clarkson A, Muljono A, Meyer-Rochow GY, Richardson AL, Sidhu
285 SB, Robinson BG, Clifton-Bligh RJ. Immunohistochemistry for SDHB triages genetic testing of
286 SDHB, SDHC and SDHD in paraganglioma–pheochromocytoma. *Hum Pathol.* **2010**, 41, 805–814.
- 287 32. Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, Midorikawa S, Arao T,
288 Sugisawa C et al. Clinicopathological study of SDHB mutation-related pheochromocytoma and
289 sympathetic paraganglioma. *Endocr Relat Cancer.* **2014**, 21, L13-16.
- 290 33. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G,
291 Powers JF, Tischler AS et al. A HIF1a regulatory loop links hypoxia and mitochondrial signals in
292 pheochromocytomas. *PLoS Genetics.* **2005**, 1, 72–80.
- 293 34. Pollard PJ, et al. Expression of HIF-1, HIF-2(EPAS1), and their target genes in paraganglioma
294 and pheochromocytoma with VHL and SDH mutations. *J Clin Endocrinol Metab.* **2006**, 91,
295 4593–4598.
- 296 35. Korpershoek E, et al.: SDHA immunohistochemistry detects germline SDHA gene mutations in
297 apparently sporadic paragangliomas and pheochromocytomas. *J Clin Endocrinol Metab.* **2011**, 96:
298 E1472-1476.
- 299 36. Kimura, N. A pathologist's view: molecular profiles for diagnosing pheochromocytomas and
300 paragangliomas. *Int J Endo Oncol.* **2015**, 2, 193-200.
- 301 37. Eisenhofer G, Tischler A, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma
302 and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. *Endocr*
303 *Pathol.* **2012**, 23, 4-14.
- 304 38. Noltong S, Grossman AB. Signaling pathways in pheochromocytomas and paragangliomas:
305 prospects for future therapies. *Endocr. Pathol.* **2012**, 23, 21–33.
- 306 39. Favier J, Igaz P, Burnichon N. et al. Rationale for anti-angiogenic therapy in pheochromocytoma
307 and paraganglioma. *Endocr. Pathol.* **2012**, 23, 34–42.
- 308 40. Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic
309 heterogeneity. *Nat. Rev. Cancer* **2014**, 14, 108–119.